Evaluation of immunogenicity, efficacy and safety of GP40041 compared to Humulin® NPH in patients with type 2 diabetes mellitus

• मुख्य लेखकों: A. G. Zalevskaya (लेखक), A. A. Mosikian (लेखक), O. V. Afonkina (लेखक), R. V. Drai (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Izdatelstvo OKI, 2019-08-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Background. GP40041 is a biosimilar to Humulin® NPH. GP40041 is registered and administrated in Russia since 2004. However, due to changes in the regulatory requirements for biosimilar insulin development programme, we have conducted additional clinical trials of GP40041 including a comparative clin...